Please assess the completion status of the following clinical trial:

Trial Title: Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes with Hemoglobin A1c equal to or less than 9.5% (equal to or less than 81 mmol/mol)~* Anti-hyperglycemic drug naive or treated with up to 2 oral hyperglycemic drugs with or without a glucagon-like peptide-1analog or basal insulin, or basal insulin alone~* On stable antihyperglycemic regimen for at least 3 months~* Age equal to or greater than 50 years with established clinical vascular disease, or age equal to or greater than 55 years and subclinical vascular disease or age equal to or greater than 60 years and at least 2 or more cardiovascular risk factors~Exclusion Criteria:~* Uncontrolled diabetes requiring immediate therapy~* History of severe hypoglycemia in past year~* Acute coronary or cerebrovascular event within past 2 months~* Planned or anticipated revascularization procedure~* History of pancreatitis, hepatic insufficiency , chronic renal failure or of C-cell thyroid disorder~* Pregnancy or planned pregnancy during the trial period~* Completed or withdrawn from any study investigating dulaglutide

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.5 mg Dulaglutide (Type: EXPERIMENTAL): Administered once weekly, subcutaneously
- Placebo (Type: PLACEBO_COMPARATOR): Administered once weekly, subcutaneously

Based on this trial design, predict the completion outcome and termination type (if applicable).